Literature DB >> 23679312

Orphan nuclear receptor nurr1 as a potential novel marker for progression in human prostate cancer.

Jian Wang1, Jing Yang, Ying Zou, Guo-Liang Huang, Zhi-Wei He.   

Abstract

A number of studies have indicated that Nurr1, which belongs to a novel class of orphan nuclear receptors (the NR4A family), is important for carcinogenesis. Here we investigated expression of Nurr1 protein in benign and malignant human prostate tissues and association with clinicopathologic features using immunohistochemical techniques. Moreover, we also investigated the ability of Nurr1 to influence proliferation, migration, invasion and apoptosis of human prostate cancer cells using small interfering RNA silencing. Immunohistochemical analysis revealed that the expression of Nurr1 protein was higher in prostate cancer tissues than in benign prostate tissue (P < 0.001), levels being positively correlated with tumor T classification (P = 0.003), N classification (P = 0.017), M classification (P = 0.011) and the Gleason score (P = 0.020) of prostate cancer patients. In vitro, silencing of endogenous Nurr1 attenuated cell proliferation, migration and invasion, and induced apoptosis of prostate cancer cells. These results suggest that Nurr1 may be used as an indicator for prostate cancer progression and be useful for novel potential therapeutic strategies.

Entities:  

Mesh:

Substances:

Year:  2013        PMID: 23679312     DOI: 10.7314/apjcp.2013.14.3.2023

Source DB:  PubMed          Journal:  Asian Pac J Cancer Prev        ISSN: 1513-7368


  17 in total

1.  Clinical implications of pretreatment inflammatory biomarkers as independent prognostic indicators in prostate cancer.

Authors:  Zhaohui Sun; Ying Ju; Fuyan Han; Xiya Sun; Fang Wang
Journal:  J Clin Lab Anal       Date:  2017-06-12       Impact factor: 2.352

Review 2.  Nuclear receptors in cancer - uncovering new and evolving roles through genomic analysis.

Authors:  Vineet K Dhiman; Michael J Bolt; Kevin P White
Journal:  Nat Rev Genet       Date:  2017-12-27       Impact factor: 53.242

3.  Structural basis of binding of homodimers of the nuclear receptor NR4A2 to selective Nur-responsive DNA elements.

Authors:  Longying Jiang; Shuyan Dai; Jun Li; Xujun Liang; Lingzhi Qu; Xiaojuan Chen; Ming Guo; Zhuchu Chen; Lin Chen; Hudie Wei; Yongheng Chen
Journal:  J Biol Chem       Date:  2019-11-13       Impact factor: 5.157

4.  Clinicopathological significance of orphan nuclear receptor Nurr1 expression in gastric cancer.

Authors:  J Guo; G Zu; T Zhou; J Xing; Z Wang
Journal:  Clin Transl Oncol       Date:  2015-05-29       Impact factor: 3.405

5.  Orphan nuclear receptor Nurr1 as a potential novel marker for progression in human pancreatic ductal adenocarcinoma.

Authors:  Li Ji; Chen Gong; Liangyu Ge; Linping Song; Fenfen Chen; Chunjing Jin; Hongyan Zhu; Guoxiong Zhou
Journal:  Exp Ther Med       Date:  2016-12-13       Impact factor: 2.447

6.  Nuclear receptor 4A (NR4A) family - orphans no more.

Authors:  Stephen Safe; Un-Ho Jin; Benjamin Morpurgo; Ala Abudayyeh; Mandip Singh; Ronald B Tjalkens
Journal:  J Steroid Biochem Mol Biol       Date:  2015-04-23       Impact factor: 4.292

Review 7.  Minireview: role of orphan nuclear receptors in cancer and potential as drug targets.

Authors:  Stephen Safe; Un-Ho Jin; Erik Hedrick; Alexandra Reeder; Syng-Ook Lee
Journal:  Mol Endocrinol       Date:  2013-12-02

Review 8.  Molecular Insights into NR4A2(Nurr1): an Emerging Target for Neuroprotective Therapy Against Neuroinflammation and Neuronal Cell Death.

Authors:  Md Jakaria; Md Ezazul Haque; Duk-Yeon Cho; Shofiul Azam; In-Su Kim; Dong-Kug Choi
Journal:  Mol Neurobiol       Date:  2019-01-25       Impact factor: 5.590

9.  Nuclear receptor 4A2 (NR4A2) is a druggable target for glioblastomas.

Authors:  Keshav Karki; Xi Li; Un-Ho Jin; Kumaravel Mohankumar; Mahsa Zarei; Sharon K Michelhaugh; Sandeep Mittal; Ronald Tjalkens; Stephen Safe
Journal:  J Neurooncol       Date:  2019-11-21       Impact factor: 4.130

10.  Drug screening to target nuclear orphan receptor NR4A2 for cancer therapeutics.

Authors:  Takefumi Komiya; Satomi Yamamoto; Anuradha Roy; Peter McDonald; Raymond P Perez
Journal:  Transl Lung Cancer Res       Date:  2017-10
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.